Epcoritamab monotherapy in patients with relapsed or refractory follicular lymphoma (EPCORE NHL-1): a phase 2 cohort of a single-arm, multicentre studyKim Linton, Julie M. Vose, Martin Hutchings et al.|The Lancet Haematology|2024Cited by 134
Epcoritamab SC Monotherapy Leads to Deep and Durable Responses in Patients with Relapsed or Refractory Follicular Lymphoma: First Data Disclosure from the Epcore NHL-1 Follicular Lymphoma Dose-Expansion CohortKim Linton, Catherine Thiéblemont, Wojciech Jurczak et al.|Blood|2023Cited by 38
<scp><i>NOTCH1</i></scp> Mutations Are Associated With Therapy‐Resistance in Patients With B‐Cell Lymphoma Treated With <scp>CD20xCD3</scp> Bispecific AntibodiesEmil Ramsø Kyvsgaard, Simon Husby, Morten Grauslund et al.|American Journal of Hematology|2025Cited by 4
Real-world outcomes with ibrutinib in relapsed or refractory mantle cell lymphoma: a Danish population-based studyTrine Trab, Kirsten Grønbæk, Iman Chanchiri et al.|Blood Neoplasia|2025Cited by 4
NOTCH1 Mutations Are Associated with Therapy-Resistance in Patients with B-Cell Lymphoma Treated with CD20xCD3 Bispecific AntibodiesEmil Ramsø Kyvsgaard, Simon Husby, Morten Grauslund et al.|Blood|2024Cited by 1